<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549156</url>
  </required_header>
  <id_info>
    <org_study_id>201805096</org_study_id>
    <nct_id>NCT03549156</nct_id>
  </id_info>
  <brief_title>Comparison of a Two Ready-to-use Supplementary Foods of Differing Protein Quality for the Treatment of MAM.</brief_title>
  <official_title>Comparison of a Two Ready-to-use Supplementary Foods of Differing Protein Quality for the Treatment of Moderate Acute Malnutrition in Rural Malawian Children: a Randomised, Investigator-blinded, Clinical Effectiveness Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Malawi College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Project Peanut Butter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomised, double-blinded, controlled clinical effectiveness trial of
      two supplementary foods in the treatment of MAM. The setting will be 21 rural sites in
      southern Malawi. The participants will be 1800 children 6-59 months old with MAM, defined as
      mid-upper arm circumference (MUAC) ≥ 11.5 cm and &lt; 12.5 cm and/or a weight-for-height Z-score
      (WHZ) between -2 and -3 without bipedal edema. Children will receive approximately 75
      kcal/kg/d (314 kJ/kg/d) of one of two RUSFs in two-week rations for outpatient therapy of
      MAM. The two supplements will be a novel, locally produced peanut/dairy RUSFs, one with a
      high protein quality (HIPRO RUSF) or one with a standard protein quality, referred to as
      control RUSF (C-RUSF). The primary outcome measures will be recovery from MAM (achieving MUAC
      ≥ 12.5 cm and/or WHZ&gt;-2 by 12 weeks) or failure (death, development of severe acute
      malnutrition, transfer to hospital for inpatient care, failure to recover from MAM by 12
      weeks, default). Secondary outcome measures include rates of weight, height, and
      mid-upper-arm circumference (MUAC) gain, time to graduation, and adverse effects from the
      supplementary foods.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Actual">March 8, 2019</completion_date>
  <primary_completion_date type="Actual">March 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Each food will be randomized to two colors with the study coordinator, nurse, caregivers blinded to the which color is which food.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery from Moderate Acute Malnutrition using Mid-Upper Arm Circumference (MUAC) and Weight for Height Z score (WHZ)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants achieving a Mid-Upper Arm Circumference (MUAC) ≥ 12.5 cm and/or WHZ&gt;-2 within a 12 week treatment period</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1858</enrollment>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>C-RUSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control/Standard RUSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIPRO RUSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>New RUSF product</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>C-RUSF</intervention_name>
    <description>-RUSF contains whey permeate, WPC 80, peanut paste, sugar, soy oil, canola oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier</description>
    <arm_group_label>C-RUSF</arm_group_label>
    <other_name>Ready-to-use supplementary food</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HIPRO RUSF</intervention_name>
    <description>HIPRO RUSF contains extruded soy flour, skimmed milk, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate</description>
    <arm_group_label>HIPRO RUSF</arm_group_label>
    <other_name>Ready-to-use supplementary food</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MUAC &lt; 12.5 cm and ≥ 11.5 cm

          -  without bipedal edema

        Exclusion Criteria:

          -  simultaneously involved in another research trial or supplemental feeding program

          -  developmentally delayed, have a chronic debilitating illness such as cerebral palsy

          -  history of peanut or milk allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Manary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine in St. Louis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Feeding Clinics</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate Acute Malnutrition, Malnutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

